Sitemap
- Home
- Our Products
- Our Company
- Management Strategy
- Corporate Profile
- Management Profiles
- Key Partners
- Scientific Advisory Board
- Investor Relations
- Shareholders Communication
- Investor Relations Contacts
- Press Releases
- October 4, 2011 - Mymetics reclaims innovative intra-nasal influenza vaccine
- May 26, 2011 - Completion of Successful Phase I Study
- March 7, 2011 - Copy of 8 K file with SEC regarding OTC listing
- February 15, 2011 - Publication in scientific journal Immunity
- November 29, 2010 - Mymetics Secures New Patent for Virosome based Vaccines
- November 30, 2010 - Mymetics HIV Vaccine Shows Strong Preliminary Phase I Data
- September 13, 2010 - Mymetics’ novel HIV vaccine to begin new NIH-funded study at University of California, Davis
- August 11, 2010 - Mymetics Corporation announces new Chief Financial Officer
- June 28, 2010 - Mymetics’ Respiratory Syncytial Virus (RSV) vaccine protects from viral challenge in pre-clinical study
- June 16, 2010 - Mymetics’ Phase Ib Malaria Vaccine: Safe, Well Tolerated and Long-Lasting Antibody Response in Children in Tanzania
- January 19, 2010 - Mymetics Corporation: the First Human Vaccinations of Mymetics’ Preventative HIV Vaccine Candidate are well tolerated
- October 20, 2009 - Mymetics Corporation presents ground breaking results with preventative HIV vaccine at the World AIDS Vaccine Congress in Paris 19 – 22 October
- September 8, 2009 -- Mymetics Corporation announces the appointment of Dr. Stanley Plotkin as Chairman of the Scientific Advisory Board and election of new members
- June 22, 2009 -- Mymetics Corporation's Board of Directors announces the Appointment of Jacques-François Martin as President and CEO
- March 9, 2009 -- Mymetics Corporation acquires Virosome Biologicals B.V.
- February 9, 2009 -- Mymetics Corporation announces success of its preventive vaccine against HIV/AIDS and commencement of European phase 1 Human Clinical trials
- December 09, 2008 -- Mymetics Corporation Retains Lazard Bank to further the Company's merger, acquisition and expansion activities
- December 03, 2008 -- Mymetics Corporation announces initial research coverage by Khandaker Partners
- September 23, 2008 -- Mymetics Corporation now Blue Sky registered in 44 States
- September 16, 2008 -- Successful Results for Mymetics Corporation’s Mucosal HIV/AIDS vaccine ViralChallenge significantly exceeds expectations
- July 31, 2008 -- Letter to the Shareholders
- May 19, 2008 -- Mymetics Corporation Acquires Preventive Malaria Vaccine From Pevion Biotech AG (Switzerland)
- February 14, 2008 -- MA European Healthcare Consortium, including MYMETICS Corporation, awarded €7.50 Million grant
- June 29, 2007 -- Mymetics Expands Board of Directors with the Addition of Dr. Thomas Staehelin
- June 07, 2007 -- Mymetics'HIV Vaccine Demonstrates First-Ever Production of Mucosal Neutralizing IgA Antibodies in Non-human Primate Model
- March 29, 2007 -- Mymetics'HIV Vaccine Achieves Research Breakthrough, Eliciting Protective Antibody Response in Mucosal Tissues of Non-Human Primate Model
- March 09, 2006 -- NIH Plan to test HIV-AIDS Vaccine
- Press Articles & Publications
- Filings
- Shareholders Communication
- Contact us
Standard&Poors - Analysis Report
To see the latest S&P report on Mymetics, click here:
